Journal of Reproduction & Infertility

Journal of Reproduction & Infertility

Multiple Mutations in Exon-2 of Med-12 Identified in Uterine Leiomyomata

Authors
1 Department of Genetics and Molecular Medicine, Vasavi Medical and Research Center, Lakdi-ka-pool, Hyderabad, India; Department of Biotechnology, Hyderabad Science Society, Hyderabad, India; Department of Genetics, Osmania Universi
2 Department of Gynaecology and Obstetrics, Medicover Hospitals, Hi–Tech City, Hyderabad, India
3 Department of Genetics and Molecular Medicine, Vasavi Medical and Research Center, Lakdi-ka-pool, Hyderabad, India; Department of Genetics, Osmania University, Hyderabad, India
4 Department of Biotechnology, Hyderabad Science Society, Hyderabad, India; Department of Genetics, Osmania University, Hyderabad, India; Department of Genetics and Molecular Medicine, Kamineni Hospital, LB Nagar, Hyderabad, India
Abstract
Background: Uterine leiomyomata (UL), commonly known as uterine fibroids, are benign smooth muscle tumors of the myometrium. They cause pelvic pain, abnormal uterine bleeding, and infertility in women of reproductive age. The ovarian hormone estrogen is the main stimulator for the fibroid growth. The etiology is not yet clearly understood; however, UL are believed to be monoclonal tumors arising from a common progenitor cell. Chromosomal cytogenetic abnormalities have been demonstrated in 40-50% of the fibroids. The most frequent tumor specific genetic alterations in UL were identified in exon-2 of Mediator Complex Subunit 12 (MED-12). Methods: In the present study, twenty-two multiple fibroids were evaluated both from the same uterus and from different uteri, of four women, for somatic mutations in hotspot region of MED-12. The tissue DNA of the UL's was isolated, amplified by PCR visualized on gel and sent for Sanger sequencing. Results: The results indicate several variants in exon-2 and flanking intronic regions, seven exonic variants and five intronic variants which provide evidence that multiple UL in the same uterus may not be clonal in origin. Conclusion: This study indicates genetic heterogeneity. UL may not have a clonal origin, these exon-2 variants of MED-12 gene could be involved in UL progression.
Keywords

  1. Flake GP, Andersen J, Dixon D. Etiology and pathogenesis of uterine leiomyomas: a review. Environ Health Perspect. 2003;111(8):1037-54.
  2. Stewart EA. Uterine fibroids. Lancet. 2001;357(9252):293-8.
  3. Wallach EE, Vlahos NF. Uterine myomas: an overview of development, clinical features, and management. Obstet Gynecol. 2004:104(2):393-406.
  4. Walker CL. Role of hormonal and reproductive factors in the etiology and treatment of uterine leiomyoma. Recent Prog Horm Res. 2002;57:277-94.
  5. Shaik NA, Lone WG, Khan IA, Vaidya S, Rao KP, Kodati VL, et al. Detection of somatic mutations and germline polymorphisms in mitochondrial DNA of uterine fibroids patients. Genetic Test Mol Biomarkers. 2011;15(7-8):537-41.
  6. Makinen N, Mehine M, Tolvanen J, Kaasinen E, Li YL, Lehtonen HJ, et al. MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas. Science. 2011;334(6053):252-5.
  7. Croce S, Chibon F. MED12 and uterine smooth muscle oncogenesis: state of the art and perspectives. Eur J Cancer. 2015;51(12):1603-10.
  8. Mehine M, Kaasinen E, Heinonen HR, Mäkinen N, Kämpjärvi K, Sarvilinna N, et al. Integrated data analysis reveals uterine leiomyoma subtypes with distinct driver pathways and biomarkers. Proc Natl Acad Sci USA. 2016;113(5):1315-20.
  9. Darooei M, Khan F, Rehan M, Zubeda S, Jeyashanker E, Annapurna S, et al. MED12 somatic mutations encompassing exon 2 associated with benign breast fibroadenomas and not breast carcinoma in Indian women. J Cell Biochem. 2019;120(1):182-91.
  10. Noor Ahmad S, Sujatha G, Vijaylakshmi K, Kaipa Prabhakar R, Qurratulain H. Polymorphic (CAG)n repeats in the androgen'receptor gene: a risk marker for endometriosis and uterine leiomyomas. Hematol Oncol Stem Cell Ther. 2009;2(1):289-93.
  11. Lim WK, Ong CK, Tan J, Thike AA, Ng CC, Rajasegaran V, et al. Exome sequencing identifies highly recurrent MED12 somatic mutations in breast fibroadenoma. Nat Genet. 2014;46(8):877-80.
  12. Mäkinen N, Vahteristo P, Kämpjärvi K, Arola J, Bützow R, Aaltonen LA. MED12 exon 2 mutations in histopathological uterine leiomyoma variants. Eur J Hum Genet. 2013;21(11):1300-3.
  13. Conaway RC, Conaway JW. Function and regulation of the mediator complex. Curr Opin Genet Dev. 2011;21(2):225-30.
  14. Taatjes DJ. The human mediator complex: a versatile, genome-wide regulator of transcription. Trends Biochem Sci. 2010;35(6):315-22.
  15. Näär AM, Taatjes DJ, Zhai W, Nogales E, Tjian R. Human CRSP interacts with RNA polymerase II CTD and adopts a specific CTD-bound conformation. Genes Dev. 2002;16(11):1339-44.
  16. Zhang X, Krutchinsky A, Fukuda A, Chen W, Yamamura S, Chait BT, et al. MED1/TRAP220 exists predominantly in a TRAP/Mediator subpopulation enriched in RNA polymerase II and is required for ER-mediated transcription. Mol Cell. 2005;19(1):89-100.
  17. Malik S, Baek HJ, Wu W, Roeder RG. Structural and functional characterization of PC2 and RNA polymerase II-associated subpopulations of metazoan mediator. Mol Cll Biol. 2005;25(6):2117-29.
  18. Baek HJ, Kang YK, Roeder RG. Human mediator enhances basal transcription by facilitating recruitment of transcription factor IIB during preinitiation complex assembly. J Biol Chem. 2006;281(22):15172-81.
  19. Johnson KM, Wang J, Smallwood A, Arayata C, Carey M. TFIID and human mediator coactivator complexes assemble cooperatively on promoter DNA. Genes Dev. 2002;16(14):1852-63.
  20. Meyer KD, Lin SC, Bernecky C, Gao Y, Taatjes DJ. p53 activates transcription by directing structural shifts in mediator. Nat Struct Mol Biol. 2010;17(6):753-60.
  21. Turunen M, Spaeth JM, Keskitalo S, Park MJ, Kivioja T, Clark AD, et al. Uterine leiomyoma-linked MED12 mutations disrupt mediator-associated CDK activity. Cell Rep. 2014;7(3):654-60.
  22. Kämpjärvi K, Park MJ, Mehine M, Kim NH, Clark AD, Bützow R, et al. Mutations in Exon 1 highlight the role of MED 12 in uterine leiomyomas. Hum Mutat. 2014;35(9):1136-41.
  23. Cani AK, Hovelson DH, McDaniel AS, Sadis S, Haller MJ, Yadati V, et al. Next-gen sequencing exposes frequent MED12 mutations and actionable therapeutic targets in phyllodes tumors. Mol Cancer Res. 2015;13(4):613-9.
  24. Pfarr N, Kriegsmann M, Sinn P, Klauschen F, Endris V, Herpel E, et al. Distribution of MED12 mutations in fibroadenomas and phyllodes tumors of the breast—implications for tumor biology and pathological diagnosis. Genes Chromosomes Cancer. 2015;54(7):444-52.
  25. McGuire MM, Yatsenko A, Hoffner L, Jones M, Surti U, Rajkovic A. Whole exome sequencing in a random sample of North American women with leiomyomas identifies MED12 mutations in majority of uterine leiomyomas. PloS One. 2012;7(3):e33251.
  26. Mäkinen N, Heinonen HR, Moore S, Tomlinson IP, Van Der Spuy ZM, Aaltonen LA. MED12 exon 2 mutations are common in uterine leiomyomas from South African patients. Oncotarget. 2011;2(12):966-9.
  27. Mäkinen N, Vahteristo P, Bützow R, Sjöberg J, Aaltonen LA. Exomic landscape of MED12 mutation‐negative and‐positive uterine leiomyomas. Int J Cancer. 2014;134(4):1008-12.
  28. Ajabnoor G, Mohammed NA, Banaganapalli B, Abdullah LS, Bondagji ON, Mansouri N, et al. Expanded somatic mutation spectrum of MED12 gene in Uterine Leiomyomas of Saudi Arabian Women. Front Genet. 2018;9:552.
  29. Je EM, Kim MR, Min KO, Yoo NJ, Lee SH. Mutational analysis of MED12 exon 2 in uterine leiomyoma and other common tumors. Int J Cancer. 2012;131(6):E1044-7.
  30. Markowski DN, Bartnitzke S, Löning T, Drieschner N, Helmke BM, Bullerdiek J. MED12 mutations in uterine fibroids—their relationship to cytogenetic subgroups. Int J Cancer. 2012;131(7):1528-36.
  31. Schwetye KE, Pfeifer JD, Duncavage EJ. MED12 exon 2 mutations in uterine and extrauterine smooth muscle tumors. Hum Pathol. 2014;45(1):65-70.
  32. Halder SK, Laknaur A, Miller J, Layman LC, Diamond M, Al-Hendy A. Novel MED12 gene somatic mutations in women from the Southern United States with symptomatic uterine fibroids. Mol Genet Genomics. 2015;290(2):505-11.
  33. Perot G, Croce S, Ribeiro A, Lagarde P, Velasco V, Neuville A, et al. MED12 alterations in both human benign and malignant uterine soft tissue tumors. PloS One. 2012;7(6):e40015.
  34. Bertsch E, Qiang W, Zhang Q, Espona-Fiedler M, Druschitz S, Liu Y, et al. MED12 and HMGA2 mutations: two independent genetic events in uterine leiomyoma and leiomyosarcoma. Mod Pathol. 2014;27(8):1144-53.
  35. Kim S, Xu X, Hecht A, Boyer TG. Mediator is a transducer of Wnt/β-catenin signaling. J Biol Chem. 2006;281(20):14066-75.
  36. Al-Hendy A, Laknaur A, Diamond MP, Ismail N, Boyer TG, Halder SK. Silencing Med12 gene reduces proliferation of human leiomyoma cells mediated via Wnt/β-catenin signaling pathway. Endocrinology. 2017;158(3):592-603.
  37. Piscuoglio S, Murray M, Fusco N, Marchiò C, Loo FL, Martelotto LG, et al. MED12 somatic mutations in fibroadenomas and phyllodes tumours of the breast. Histopathology. 2015;67(5):719-29.
  38. Mittal P, Shin YH, Yatsenko SA, Castro CA, Surti U, Rajkovic A. Med12 gain-of-function mutation causes leiomyomas and genomic instability. J Clin Invest. 2015;125(8):3280-4.
  39. Laé M, Gardrat S, Rondeau S, Richardot C, Caly M, Chemlali W, et al. MED12 mutations in breast phyllodes tumors: evidence of temporal tumoral heterogeneity and identification of associated critical signaling pathways. Oncotarget. 2016;7(51):84428-38.
  40. Zia A, Moses AM. Ranking insertion, deletion and nonsense mutations based on their effect on genetic information. BMC Bioinformatics. 2011;12:229.
  41. Knight JC. Functional implications of genetic variation in non-coding DNA for disease susceptibility and gene regulation. Clin Sci (Lond). 2003;104(5):493-501.
  42. Dermitzakis ET, Reymond A, Antonarakis SE. Conserved non-genic sequences—an unexpected feature of mammalian genomes. Nat Rev Genet. 2005;6(2):151-7.
  43. Drake JA, Bird C, Nemesh J, Thomas DJ, Newton-Cheh C, Reymond A, et al. Conserved noncoding sequences are selectively constrained and not mutation cold spots. Nat Genet. 2006;38(2):223-7.